Intravenous Administration of REOLYSIN® in Combination with Cyclophosphamide for Patients with Advanced Malignancies
In May 2008, Oncolytics announced that it had started patient enrollment in a clinical trial in the UK using intravenous administration of REOLYSIN® in combination with cyclophosphamide.
The primary objectives of the trial include determining the minimum effective immunomodulatory dose (MED) of cyclophosphamide to obtain successful immune modulation. Secondary objectives include assessing the safety profile of the combination and gathering any evidence of antitumor activity.
- August 16, 2012: Oncolytics Biotech® Inc. Completes Patient Enrollment in U.K. Phase I Clinical Trial Investigating REOLYSIN® in Combination with Cyclophosphamide in Patients with Advanced Malignances (Press Release)
- May 9, 2008: Oncolytics Biotech Inc. Starts Patient Enrollment in UK Combination REOLYSIN®/Cyclophosphamide Trial (Press Release)